Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Immucell (ICCC) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Immucell (ICCC) over the last 16 years, with Q3 2025 value amounting to $2.3 million.

  • Immucell's Operating Expenses rose 855.13% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year increase of 2261.62%. This contributed to the annual value of $9.6 million for FY2024, which is 37.6% down from last year.
  • As of Q3 2025, Immucell's Operating Expenses stood at $2.3 million, which was up 855.13% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Immucell's Operating Expenses registered a high of $2.6 million during Q4 2022, and its lowest value of $1.9 million during Q2 2021.
  • Over the past 5 years, Immucell's median Operating Expenses value was $2.3 million (recorded in 2023), while the average stood at $2.3 million.
  • Per our database at Business Quant, Immucell's Operating Expenses surged by 2811.6% in 2022 and then tumbled by 1408.93% in 2025.
  • Over the past 5 years, Immucell's Operating Expenses (Quarter) stood at $2.4 million in 2021, then increased by 8.72% to $2.6 million in 2022, then dropped by 6.66% to $2.5 million in 2023, then dropped by 9.82% to $2.2 million in 2024, then grew by 6.01% to $2.3 million in 2025.
  • Its last three reported values are $2.3 million in Q3 2025, $2.2 million for Q2 2025, and $2.2 million during Q1 2025.